Johnson & Johnson nears multi-billion dollar opioids settlement

21 July 2021
addiction_pills_syringe_big

USA-based healthcare giant Johnson & Johnson (NYSE: JNJ), together with three major drug distributors, are ready to agree to a $26 billion settlement in connection with lawsuits over the ongoing opioid epidemic.

According to the Associated Press, people with an understanding of the arrangements have revealed that J&J would pay $5 billion, while AmerisourceBergen, Cardinal Health and McKesson would pay a combined total of $21 billion.

J&J would pay the money over a period of nine years, while the drug distributors would have a full 18 years to discharge their commitments.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical